EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chondrogenesis of Peripheral Blood-Derived Mesenchymal Stromal Cells

Harish V K Ratna iD, Madhan Jeyaraman iD, Naveen Jeyaraman iD, Arulkumar Nallakumarasamy iD, Luise Schäfer, Filippo Migliorini iD, Sathish Muthu iD

Cells · 06.03.2026 · 15 (5) · 476

DOI: 10.3390/cells15050476 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 06.03.2026. Verfasst von Harish V K Ratna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Chondrogenesis. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Articular cartilage, a highly specialised and avascular tissue, exhibits limited regenerative potential following trauma or degenerative conditions such as osteoarthritis (OA). Conventional surgical interventions, including microfracture and autologous chondrocyte implantation (ACI), have shown limited long-term efficacy due to donor site morbidity and restricted cell proliferation. In this context, mesenchymal stromal cells (MSCs) have emerged as a promising alternative owing to their multipotency, self-renewal capacity, and low immunogenicity. While bone marrow (BM) remains the traditional source of MSCs, recent studies have reported that peripheral blood-derived mesenchymal stromal cells (PB-MSCs) may possess chondrogenic, osteogenic, and adipogenic potential comparable to that of BM-derived MSCs. PB-MSCs can be harvested through minimally invasive methods, thereby avoiding the complications associated with BM aspiration. Experimental evidence indicates that PB-MSCs exhibit strong cell viability, proliferative potential, and the ability to synthesise cartilage-specific extracellular matrix proteins, such as type II collagen and sulphated glycosaminoglycans, within three-dimensional scaffolds. Immunophenotypically, PB-MSCs express mesenchymal markers including CD29, CD44, CD90, and CD105 while lacking hematopoietic markers CD34 and CD45. Flow cytometry analyses reveal that CD105+ populations increase following cryopreservation, highlighting their clinical utility. In contrast to these experimentally defined PB-MSCs, the term peripheral blood stem cells (PBSCs) is used in clinical studies to describe heterogeneous, non-cultured peripheral blood-derived cell preparations, typically enriched in hematopoietic stem and progenitor cells following granulocyte colony-stimulating factor (G-CSF) mobilisation, without full mesenchymal characterisation. In vitro studies confirm successful tri-lineage differentiation, whereas in vivo investigations have demonstrated effective cartilage regeneration using PB-based clinical approaches, including postoperative intra-articular administration of hyaluronic acid (HA) combined with PBSCs, as well as implantation of PBSCs covered with a collagen membrane. Furthermore, advancements in biomaterial engineering, such as poly(ethylene glycol)–cysteine–arginine–glycine–aspartic acid (PEG-CRGD) hydrogels, have enhanced PB-MSC adhesion, proliferation, and chondrogenic differentiation while promoting immunomodulation through M2 macrophage polarisation. Despite these promising outcomes, the available evidence remains limited and heterogeneous, with substantial variability in cell definitions, experimental models, and clinical study designs, which currently constrains definitive conclusions regarding clinical efficacy. Future research should focus on optimising isolation protocols, understanding molecular pathways governing PB-MSC chondrogenesis, and standardising clinical applications. Overall, PB-MSCs represent a viable, less invasive, and translationally relevant cell source for cartilage regeneration and regenerative orthopaedic therapies

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsChondrogenesisHumansAnimalsCell Differentiation

Stichwörter der Autor:innen

SOXchondrogenesisextracellular matrixmesenchymal stromal cellsperipheral blood

Autor:innen und Institutionen

  • Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India.
  • Department of Regenerative Medicine, Agathisha Institute of Stemcell and Regenerative Medicine (AISRM), Chennai 600030, Tamil Nadu, India.
  • Department of Orthopaedics, Orthopaedic Research Group, Coimbatore 641045, Tamil Nadu, India.
  • Department of Orthopaedics, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Karaikal 609602, Puducherry, India.
  • Department of Orthopaedic and Trauma Surgery, Eifelklinik St. Brigida, Kammerbruchstr. 8, 52152 Simmerath, Germany.
  • Department of Trauma and Reconstructive Surgery, University Hospital of Halle, Martin-Luther University Halle-Wittenberg, 06097 Halle (Saale), Germany.

ORCID-Profile: Harish V K Ratna, Madhan Jeyaraman, Naveen Jeyaraman, Arulkumar Nallakumarasamy, Filippo Migliorini, Sathish Muthu

Zitieren

APA

Ratna, H. V. K., Jeyaraman, M., Jeyaraman, N., Nallakumarasamy, A., Schäfer, L., Migliorini, F., & Muthu, S. (2026). Chondrogenesis of Peripheral Blood-Derived Mesenchymal Stromal Cells. Cells, 15(5), 476. https://doi.org/10.3390/cells15050476

Vancouver

Ratna HVK, Jeyaraman M, Jeyaraman N, Nallakumarasamy A, Schäfer L, Migliorini F, et al. Chondrogenesis of Peripheral Blood-Derived Mesenchymal Stromal Cells. Cells. 2026;15(5):476. doi:10.3390/cells15050476

BibTeX
@article{Ratna2026,
  author = {Ratna, Harish V K and Jeyaraman, Madhan and Jeyaraman, Naveen and Nallakumarasamy, Arulkumar and Schäfer, Luise and Migliorini, Filippo and Muthu, Sathish},
  title = {Chondrogenesis of Peripheral Blood-Derived Mesenchymal Stromal Cells},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {5},
  pages = {476},
  doi = {10.3390/cells15050476}
}
Kostenlos starten →